FdaApplication
NDA 022264
Identifiers
- fda_app_no: NDA022264
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2009-07-31 |
Revenue by product
INVEGA SUSTENNA
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $1.0B |
| Q4 2025 | $986.0M |
| Q3 2025 | $929.0M |
| Q2 2025 | $992.0M |
| Q1 2025 | $903.0M |
| Q4 2024 | $1.1B |
| Q3 2024 | $1.0B |
| Q2 2024 | $1.1B |
| Q1 2024 | $1.1B |
| Q4 2023 | $1.0B |
| Q3 2023 | $1.0B |
| Q2 2023 | $1.0B |
| Q1 2023 | $1.0B |
| Q4 2022 | $1.0B |
| Q3 2022 | $1.0B |
| Q2 2022 | $1.1B |
| Q1 2022 | $1.0B |
| Q4 2021 | $1.0B |
| Q3 2021 | $1.0B |
| Q2 2021 | $1.0B |
| Q1 2021 | $965.0M |
| Q4 2020 | $965.0M |
| Q3 2020 | $926.0M |
| Q2 2020 | $879.0M |
| Q1 2020 | $883.0M |
| Q4 2019 | $871.0M |
| Q3 2019 | $851.0M |
| Q2 2019 | $818.0M |
| Q1 2019 | $790.0M |
| Q4 2018 | $763.0M |
| Q3 2018 | $749.0M |
| Q2 2018 | $720.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 234MG/1.5ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 78MG/0.5ML (78MG/0.5ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 39MG/0.25ML (39MG/0.25ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 117MG/0.75ML (117MG/0.75ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 156MG/ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
5 products